Startups

Ventureport Hosts Soft Launch of InvestHK’s Fast-Track Connect

Six technology companies showcased solutions for financial research, wealth management, consumer insight and security to investors and institutions.

Updated

November 14, 2026 11:54 PM

Arnold Lau and King Leung (back row, fourth and fifth from left), Associate Directors-General of Investment Promotion at InvestHK, join the Ventureport team and representatives from the six technology companies. PHOTO: VENTUREPORT

Ventureport hosted the soft launch of InvestHK’s Fast-Track Connect at its AI+ Tech+ Finance+ gathering on 30 October, bringing more than 100 guests to Pier 1929 in Wan Chai.

Sponsored by InvestHK, the event brought investors, institutional representatives and technology companies together to explore investment and business partnerships. Six companies took the stage to showcase software solutions for financial professionals, consumer research, local AI computing and digital asset security.

‍

King Leung, Associate Director-General of Investment Promotion at InvestHK, delivers opening remarks. PHOTO: VENTUREPORT

‍

Connecting companies with investors and institutions

The Acting Head of Startups, at InvestHK, Chin-yung (CY), and the Senior Vice President (Fintech), Pauline Fan, introduced Fast-Track Connect.  They explained how the agency’s international network connects it with technology companies seeking investment, customers and business opportunities in Hong Kong.

‍

Chin-yung (CY) Lu (left) and Pauline Fan (right) introduce InvestHK’s Fast-Track Connect. PHOTO: VENTUREPORT

‍

Their remarks also highlight the need for a more structured approach to build these connections. Investors need easier ways to identify companies that match their interests, while institutions seeking new technology need access to businesses whose products could support their operations or benefit their customers.  

To address this need, Fast-Track Connect provides an online platform where technology companies can publish profiles outlining their products and funding needs. Investors and corporate participants can identify relevant businesses and contact them to explore potential investments or collaborations. Service providers and community partners are also part of the platform. Alongside investors and corporate participants, these groups are designated as Champions on the platform.

Curated by InvestHK and supported by the Financial Services and the Treasury Bureau, Fast-Track Connect builds on the Global Fast Track Programme. It aims to help local enterprises expand into Chinese Mainland, Southeast Asia and other markets.

‍

Guests at Ventureport’s AI+ Tech+ Finance+ gathering. PHOTO: VENTUREPORT

‍

Financial research and client advice

AlphaPai, an AI-powered investment research platform developed by financial technology company RabyteTech, presented tools for financial research, including gathering data, monitoring financial instruments and comparing information from corporate earnings calls.

‍

AlphaPai presents its AI investment research platform. PHOTO: VENTUREPORT

‍

At the event, the team explained how users can give research instructions in everyday language, while the software retrieves and processes information to prepare reports and presentation materials. Examples included tracking market developments and comparing company statements over time. The team also emphasised the importance of traceable sources, allowing analysts to verify the information behind their research.

A2B2.AI, a fintech startup, presented AI- powered tools designed to support investors and wealth advisers. Its specialist AI agents—software designed to carry out particular tasks—help prepare client meeting briefings, monitor financial products approaching maturity and identify market developments relevant to individual clients, according to the team.

‍

A2B2.AI co-founder Teresa Goh presents tools for investors and wealth advisers. PHOTO: VENTUREPORT

‍

For investors, the tool can help make sense of lengthy documents provided by advisers and bring information from different accounts together to assess risk exposure. For wealth professionals, the tools support preparation and follow-up around client meetings.

The team described its approach as combining AI with human expertise to support financial decision- making. It also clarified that the platform does not execute investment transactions on behalf of clients, leaving those decisions and actions in their hands.  

‍

Consumer insight and local AI

Preferences AI, an AI startup specialising in synthetic consumer research, presented simulated consumer profiles that businesses can use to explore how different audiences might respond to products, pricing and marketing messages. These profiles generate modelled responses rather than feedback from people directly interviewed or surveyed.

‍

Preferences AI co-founder Tamir Abdel-wahab discusses AI for consumer research. PHOTO: VENTUREPORT

‍

The company described that its profiles are grounded in population data and account for differences between local audiences Businesses can use them to explore pricing or packaging options, as well as ask follow-up questions to understand the reasons behind a particular response. The team also discussed testing its models and working with academics to help validate the approach. It said the technology could help businesses explore consumer preferences more quickly.  

ByteFuture, an AI infrastructure startup, focused on running AI on users’ own hardware. It introduced Olares, its operating system, and Olares One, a device designed to run AI models and applications locally.

‍

ByteFuture co-founder Shayla presents Olares, a system for running AI locally to keep data private. PHOTO: VENTUREPORT

‍

Its applications included personal assistance, financial research and content creation. The team argued that users handling private documents or proprietary trading strategies may prefer to retain that material on equipment they control.

A demonstration of AI-generated video illustrated creative work the team said could run locally. It also described applications and agents available through its software marketplace.

‍

Digital assets and agent security

PureGlobal, a fintech company, addressed digital asset custody: the systems used to safeguard access to digital assets. Its team described technology for protecting access credentials and supporting offline transactions without a conventional internet connection.

‍

Chief Business Officer of PureGlobal, Larry Lundy, discusses digital asset security. PHOTO: VENTUREPORT

‍

The presentation focused on infrastructure for institutions holding and transferring digital assets, including security under different operating conditions.

SlowMist, a blockchain security firm, examined the risks of giving AI agents permission to read information and perform tasks. Its examples included malicious instructions concealed in material an agent might encounter and attacks exploiting access granted to software.

‍

Tony Tan, HK Community Lead of SlowMist, discusses AI agent security. PHOTO: VENTUREPORT

‍

The team discussed security auditing, monitoring and investigations alongside risks arising from third-party tools and an agent’s stored information. One scenario involved exposing a wallet’s recovery phrase, which can give someone control over its assets.

Keep Reading

Hong Kong

Hong Kong AI Biotech Startup METiS TechBio Draws Major Investor Demand in IPO

METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body

Updated

August 10, 2026 5:56 PM

HIV-1 virus particles, coloured red. PHOTO: UNSPLASH

Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.

The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.

Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.

The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.

That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.

METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.

The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.

One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.

Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.

METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.

The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.

Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."

The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.

For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.